Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Childhood Sciences, Psychiatry Unit, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genova.
Int J Neuropsychopharmacol. 2020 Apr 21;23(3):178-180. doi: 10.1093/ijnp/pyaa011.
The study of Roy and colleagues recently accepted for publication in International Journal of Neuropsychopharmacology is a very interesting report investigating the role of specific microRNAs (miRNAs) in vulnerability or resistance to major depressive disorder in a specific brain region (e.g., amygdala). MiRNAs may act as a mega-controller of gene expression being involved in the pathogenesis of major neuropsychiatric conditions. Interestingly, some of the altered miRNAs (e.g., hsa-miR-425-3p, miR-425, miR-674-3p, and miR-873-3p) identified in this study were found to be dysregulated even in existing studies, but several methodological issues may hamper the translation of basic research findings in clinical studies. MiRNAs are proposed as possible biomarkers of disease and treatment response to disentangle the biological complexity underlying major affective disorders. The main implications regarding the present findings are discussed.
罗伊及其同事最近在《国际神经精神药理学杂志》上发表的研究是一项非常有趣的报告，该研究调查了特定的 microRNAs（miRNAs）在特定脑区（如杏仁核）中对重度抑郁症易感性或抵抗力的作用。miRNAs 可能作为基因表达的超级控制器发挥作用，参与重大神经精神疾病的发病机制。有趣的是，在这项研究中确定的一些改变的 miRNAs（例如 hsa-miR-425-3p、miR-425、miR-674-3p 和 miR-873-3p）在现有研究中也被发现失调，但一些方法学问题可能会阻碍基础研究发现向临床研究的转化。miRNAs 被提议作为疾病的可能生物标志物和治疗反应的标志物，以阐明重度情感障碍背后的生物学复杂性。讨论了关于这些发现的主要意义。
